The same group found that endothelial activation by adhesion molecules or VEGF-A did not play a role [26], whereas, in addition, lymphangiogenesis in the intestinal tract and lymph nodes could be specifically targeted using VEGF-R-3 antibodies and ameliorated GVHD [11]. This evidence concerns the gene VEGFA and graft versus host disease.